Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via HighWire Citing Articles via Google Scholar Articles by Tsai, G. E. Articles by Coyle, J. T. Search for Related Content PubMed Citation Articles by Tsai, G. E. Articles by Coyle, J. T. Schizophrenia Spectrum Disorders Other Neuroleptics

D-Serine Added to Clozapine for the Treatment of Schizophrenia

OBJECTIVE: D-Serine is a full agonist at the glycine site on the N-methyl-D-aspartate (NMDA) receptor. Previous administration of D-serine to schizophrenic patients taking nonclozapine antipsychotics improved positive, negative, and cognitive symptoms, whereas the partial agonist D-cycloserine improved negative symptoms of patients taking conventional antipsychotics but worsened symptoms in clozapine-treated patients. To study the difference between full and partial agonists at the NMDA receptor glycine site, the clinical effects of adding D-serine to clozapine were assessed. METHOD: In a 6-week double-blind trial, 20 schizophrenic patients received placebo or D-serine (30 mg/kg per day) in addition to clozapine. Clinical efficacy, side effects, and serum levels of D-serine were determined every other week. RESULTS: The patients exhibited no improvement with D-serine, nor did their symptoms worsen, as previously reported with D-cycloserine. CONCLUSIONS: The results suggest either that clozapine may have an agonistic effect on the NMDA system or that clozapine-treated patients do not respond to D-serine.

This article has been cited by other articles:

				F. Errico, S. Rossi, F. Napolitano, V. Catuogno, E. Topo, G. Fisone, A. D'Aniello, D. Centonze, and A. Usiello D-Aspartate Prevents Corticostriatal Long-Term Depression and Attenuates Schizophrenia-Like Symptoms Induced by Amphetamine and MK-801 J. Neurosci., October 8, 2008; 28(41): 10404 - 10414. [Abstract] [Full Text] [PDF]

				G. E. Tsai, H.-Y. Lane, C. M. VanDenBerg, Y.-C. Liu, P. Tsai, and M. W. Jann Disposition of D-Serine in Healthy Adults J. Clin. Pharmacol., April 1, 2008; 48(4): 524 - 527. [Full Text] [PDF]

				R. W. Buchanan, D. C. Javitt, S. R. Marder, N. R. Schooler, J. M. Gold, R. P. McMahon, U. Heresco-Levy, and W. T. Carpenter The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): The Efficacy of Glutamatergic Agents for Negative Symptoms and Cognitive Impairments Am J Psychiatry, October 1, 2007; 164(10): 1593 - 1602. [Abstract] [Full Text] [PDF]

				J. A. Gray and B. L. Roth Molecular Targets for Treating Cognitive Dysfunction in Schizophrenia Schizophr Bull, September 1, 2007; 33(5): 1100 - 1119. [Abstract] [Full Text] [PDF]

				A. W. Krug, K. Volker, W. H. Dantzler, and S. Silbernagl Why is D-serine nephrotoxic and {alpha}-aminoisobutyric acid protective? Am J Physiol Renal Physiol, July 1, 2007; 293(1): F382 - F390. [Abstract] [Full Text] [PDF]

				P. E. Brandish, C.-S. Chiu, J. Schneeweis, N. J. Brandon, C. L. Leech, O. Kornienko, E. M. Scolnick, B. Strulovici, and W. Zheng A Cell-Based Ultra-High-Throughput Screening Assay for Identifying Inhibitors of D-Amino Acid Oxidase J Biomol Screen, August 1, 2006; 11(5): 481 - 487. [Abstract] [PDF]

				K. Hashimoto, T. Fukushima, E. Shimizu, N. Komatsu, H. Watanabe, N. Shinoda, M. Nakazato, C. Kumakiri, S.-i. Okada, H. Hasegawa, et al. Decreased Serum Levels of D-Serine in Patients With Schizophrenia: Evidence in Support of the N-Methyl-D-Aspartate Receptor Hypofunction Hypothesis of Schizophrenia Arch Gen Psychiatry, June 1, 2003; 60(6): 572 - 576. [Abstract] [Full Text] [PDF]

				L. Chen, M. Muhlhauser, and C. R. Yang Glycine Tranporter-1 Blockade Potentiates NMDA-Mediated Responses in Rat Prefrontal Cortical Neurons In Vitro and In Vivo J Neurophysiol, February 1, 2003; 89(2): 691 - 703. [Abstract] [Full Text] [PDF]

				U. Heresco-Levy, M. Ermilov, J. Shimoni, B. Shapira, G. Silipo, and D. C. Javitt Placebo-Controlled Trial of D-Cycloserine Added to Conventional Neuroleptics, Olanzapine, or Risperidone in Schizophrenia Am J Psychiatry, March 1, 2002; 159(3): 480 - 482. [Abstract] [Full Text] [PDF]

Get information about faster international access.

Privacy Policy

Copyright © 1999 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us